Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Casterella, PJ; Kereiakes, DJ; Steinhubl, SR; Raymond, RE; Kottke-Marchant, K; Patel, K; Mueller, M; Rosenthal, M; Moliterno, DJ; Teirstein, PS
   The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable
   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
   
   P.J. Casterella et al., "The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable", CATHET C IN, 54(4), 2001, pp. 497-504
2. Lincoff, AM
   Anticoagulant and antiplatelet drugs
   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
   
   A.M. Lincoff, "Anticoagulant and antiplatelet drugs", CATHET C IN, 54(4), 2001, pp. 514-520
3. McCollam, PL; Lage, MJ; Bala, M
   A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban
   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
   
   P.L. McCollam et al., "A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban", CATHET C IN, 54(2), 2001, pp. 152-157
4. Paradiso-Hardy, FL; Madan, M; Radhakrishnan, S; Hurden, S; Cohen, EA
   Severe thrombocytopenia possibly related to readministration of eptifibatide
   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
   
   F.L. Paradiso-Hardy et al., "Severe thrombocytopenia possibly related to readministration of eptifibatide", CATHET C IN, 54(1), 2001, pp. 63-67
5. Simon, DI; Liu, CB; Ganz, P; Kirshenbaum, JM; Piana, RN; Rogers, C; Selwyn, AP; Popma, JJ
   A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban
   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
   
   D.I. Simon et al., "A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban", CATHET C IN, 52(4), 2001, pp. 425-432
6. Martin, GS
   The hunting of the Src
   NATURE REVIEWS MOLECULAR CELL BIOLOGY
   
   G.S. Martin, "The hunting of the Src", NAT REV MOL, 2(6), 2001, pp. 467-475
7. Kiefel, V
   Platelet antibodies and diagnosis of immune-mediated thrombocytopenia
   INFUSION THERAPY AND TRANSFUSION MEDICINE-INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN
   
   V. Kiefel, "Platelet antibodies and diagnosis of immune-mediated thrombocytopenia", INFUS THER, 28(4), 2001, pp. 209-217
8. Inwald, D; Davies, EG; Klein, N
   Demystified ... Adhesion molecule deficiencies
   JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY
   
   D. Inwald et al., "Demystified ... Adhesion molecule deficiencies", J CL PATH-M, 54(1), 2001, pp. 1-7
9. Akkerhuis, KM; van den Brand, MJBM; van der Zwaan, C; Peels, HOJ; Suryapranata, H; van der Wieken, LR; Stibbe, J; Hoffmann, J; Baardman, T; Deckers, JW; Simoons, ML
   Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
   HEART
   
   K.M. Akkerhuis et al., "Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty", HEART, 85(4), 2001, pp. 444-450
10. Vaisman, D; Ferguson, JJ
    Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    D. Vaisman e J.J. Ferguson, "Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction", EXPERT OP I, 10(11), 2001, pp. 1965-1976
11. Nurden, P
    The anti-GPIIb-IIIa
    TRANSFUSION CLINIQUE ET BIOLOGIQUE
    
    P. Nurden, "The anti-GPIIb-IIIa", TRANSF CL B, 8(2), 2001, pp. 114-122
12. Schmidt, AM; Stern, DM
    Chemokines on the rise - MCP-1 and restenosis
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    A.M. Schmidt e D.M. Stern, "Chemokines on the rise - MCP-1 and restenosis", ART THROM V, 21(3), 2001, pp. 297-299
13. Collett, JP; Montalescot, G; Lesty, C; Soria, J; Mishal, Z; Thoms, D; Soria, C
    Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    J.P. Collett et al., "Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis", ART THROM V, 21(1), 2001, pp. 142-148
14. Abulencia, JP; Tien, N; McCarty, OJT; Plymire, D; Mousa, SA; Konstantopoulos, K
    Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    J.P. Abulencia et al., "Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis", ART THROM V, 21(1), 2001, pp. 149-156
15. Casonato, A; Pontara, E; Vertolli, UP; Steffan, A; Durante, C; De Marco, L; Sartorello, F; Girolami, A
    Plasma and platelet von Willebrand factor abnormalities in patients with uremia: Lack of correlation with uremic bleeding
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    
    A. Casonato et al., "Plasma and platelet von Willebrand factor abnormalities in patients with uremia: Lack of correlation with uremic bleeding", CL APPL T-H, 7(2), 2001, pp. 81-86
16. Santillan, MKO; Herring, J; Hoppensteadt, DA; Jeske, W; Herbert, JM; Fareed, J
    The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    
    M.K.O. Santillan et al., "The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys", CL APPL T-H, 7(1), 2001, pp. 10-15
17. Axelrod, DA; Wakefield, TW
    Future directions in antithrombotic therapy: Emphasis on venous thromboembolism
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    
    D.A. Axelrod e T.W. Wakefield, "Future directions in antithrombotic therapy: Emphasis on venous thromboembolism", J AM COLL S, 192(5), 2001, pp. 641-651
18. Burgess, JK
    Molecular mechanisms of drug-induced thrombocytopenia
    CURRENT OPINION IN HEMATOLOGY
    
    J.K. Burgess, "Molecular mechanisms of drug-induced thrombocytopenia", CURR OPIN H, 8(5), 2001, pp. 294-298
19. Spinler, SA; Hilleman, DE; Cheng, JWM; Howard, PA; Mauro, VF; Lopez, LM; Munger, MA; Gardner, SF; Nappi, JM
    New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines
    ANNALS OF PHARMACOTHERAPY
    
    S.A. Spinler et al., "New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines", ANN PHARMAC, 35(5), 2001, pp. 589-617
20. Clutton, P; Folts, JD; Freedman, JE
    Pharmacological control of platelet function
    PHARMACOLOGICAL RESEARCH
    
    P. Clutton et al., "Pharmacological control of platelet function", PHARMAC RES, 44(4), 2001, pp. 255-264
21. Bogousslavsky, J; Leclerc, JR
    Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke
    CEREBROVASCULAR DISEASES
    
    J. Bogousslavsky e J.R. Leclerc, "Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke", CEREB DIS, 11(4), 2001, pp. 287-293
22. Easton, JD
    Future perspectives for optimizing oral antiplatelet therapy
    CEREBROVASCULAR DISEASES
    
    J.D. Easton, "Future perspectives for optimizing oral antiplatelet therapy", CEREB DIS, 11, 2001, pp. 23-28
23. Knight, LC
    Radiolabeled peptide ligands for imaging thrombi and emboli
    NUCLEAR MEDICINE AND BIOLOGY
    
    L.C. Knight, "Radiolabeled peptide ligands for imaging thrombi and emboli", NUCL MED BI, 28(5), 2001, pp. 515-526
24. Hantgan, RR; Rocco, M; Nagaswami, C; Weisel, JW
    Binding of a fibrinogen mimetic stabilizes integrin alpha IIb beta 3's open conformation
    PROTEIN SCIENCE
    
    R.R. Hantgan et al., "Binding of a fibrinogen mimetic stabilizes integrin alpha IIb beta 3's open conformation", PROTEIN SCI, 10(8), 2001, pp. 1614-1626
25. Manaka, A; Sato, M; Aoki, M; Tanaka, M; Ikeda, T; Toda, Y; Yamane, Y; Nakaike, S
    2-acylimino-3H-thiazoline derivatives: A novel template for platelet GPIIb/IIIa receptor antagonists
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    A. Manaka et al., "2-acylimino-3H-thiazoline derivatives: A novel template for platelet GPIIb/IIIa receptor antagonists", BIOORG MED, 11(8), 2001, pp. 1031-1035
26. Ervin, AL; Peerschke, EIB
    Platelet activation by sustained exposure to low-dose plasmin
    BLOOD COAGULATION & FIBRINOLYSIS
    
    A.L. Ervin e E.I.B. Peerschke, "Platelet activation by sustained exposure to low-dose plasmin", BL COAG FIB, 12(6), 2001, pp. 415-425
27. Phillips, DR; Prasad, KSS; Manganello, J; Bao, M; Nannizzi-Alaimo, L
    Integrin tyrosine phosphorylation in platelet signaling
    CURRENT OPINION IN CELL BIOLOGY
    
    D.R. Phillips et al., "Integrin tyrosine phosphorylation in platelet signaling", CURR OP CEL, 13(5), 2001, pp. 546-554
28. Holmes, MB; Kabbani, SS; Terrien, CM; Watkins, MW; Sobel, BE; Schneider, DJ
    Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab
    CORONARY ARTERY DISEASE
    
    M.B. Holmes et al., "Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab", CORON ART D, 12(3), 2001, pp. 245-253
29. Lucore, CL; Trask, RV; Mishkel, GJ; Rocha-Singh, KJ; Shelton, ME; Mikell, FL; Ligon, RW
    Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital
    CORONARY ARTERY DISEASE
    
    C.L. Lucore et al., "Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital", CORON ART D, 12(2), 2001, pp. 135-142
30. Kereiakes, DJ; Lorenz, T; Young, JJ; Kukielka, G; Mueller, MN; Nanniazzi-Alaimo, L; Phillips, DR
    Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    
    D.J. Kereiakes et al., "Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban", J THROMB TH, 12(2), 2001, pp. 123-127
31. Januzzi, JL; Chae, CU; Sabatine, MS; Jang, IK
    Elevation in serum troponin I predicts the benefit of tirofiban
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    
    J.L. Januzzi et al., "Elevation in serum troponin I predicts the benefit of tirofiban", J THROMB TH, 11(3), 2001, pp. 211-215
32. Smith, BS; Gandhi, PJ
    Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins andglycoprotein IIb/IIIa receptor antagonists in renal failure
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    
    B.S. Smith e P.J. Gandhi, "Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins andglycoprotein IIb/IIIa receptor antagonists in renal failure", J THROMB TH, 11(1), 2001, pp. 39-48
33. Zhang, YH; Chung, KH; Ryu, CK; Ko, MH; Lee, MK; Yun, YP
    Antiplatelet effect of 2-chloro-3-(4-acetophenyl)-amino-1,4-naphthoquinone(NQ301): A possible mechanism through inhibition of intracellular Ca2+ mobilization
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    Y.H. Zhang et al., "Antiplatelet effect of 2-chloro-3-(4-acetophenyl)-amino-1,4-naphthoquinone(NQ301): A possible mechanism through inhibition of intracellular Ca2+ mobilization", BIOL PHAR B, 24(6), 2001, pp. 618-622
34. Mine, S; Fujisaki, T; Suematsu, M; Tanaka, Y
    Activated platelets and endothelial cell interaction with neutrophils under flow conditions
    INTERNAL MEDICINE
    
    S. Mine et al., "Activated platelets and endothelial cell interaction with neutrophils under flow conditions", INTERN MED, 40(11), 2001, pp. 1085-1092
35. Zhang, YH; Chung, KH; Ryu, CK; Lee, YH; Kim, TJ; Song, YS; Hwang, KA; Yun, YP
    Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)amino-1,4-naphthoquinone (NQ304), an antithrombotic agent
    PHARMACOLOGY & TOXICOLOGY
    
    Y.H. Zhang et al., "Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)amino-1,4-naphthoquinone (NQ304), an antithrombotic agent", PHARM TOX, 88(4), 2001, pp. 181-186
36. Nagahama, M; Nomura, S; Ozaki, Y; Yoshimura, C; Kagawa, H; Fukuhara, S
    Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus
    AUTOIMMUNITY
    
    M. Nagahama et al., "Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus", AUTOIMMUN, 33(2), 2001, pp. 85-94
37. Dai, W; Deubler, DA; Maxwell, TM; Zhu, XL; Cui, J; Rohr, LR; Stephenson, RA; Brothman, AR
    A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1
    GENOMICS
    
    W. Dai et al., "A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1", GENOMICS, 71(3), 2001, pp. 324-329
38. Missy, K; Giuriato, S; Bodin, S; Plantavid, M; Payrastre, B
    Integrins and signal transduction: illustration with the alpha(IIb)beta(3)integrin in platelets
    M S-MEDECINE SCIENCES
    
    K. Missy et al., "Integrins and signal transduction: illustration with the alpha(IIb)beta(3)integrin in platelets", M S-MED SCI, 17(2), 2001, pp. 155-161
39. Lin, PH; Bush, RL; Tong, FC; Chaikof, E; Martin, LG; Lumsden, AB
    Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab
    JOURNAL OF VASCULAR SURGERY
    
    P.H. Lin et al., "Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab", J VASC SURG, 34(5), 2001, pp. 939-942
40. Anderson, KM; Califf, RM; Stone, GW; Neumann, FJ; Montalescot, G; Miller, DP; Ferguson, JJ; Willerson, JT; Weisman, HF; Topol, EJ
    Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    
    K.M. Anderson et al., "Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention", J AM COL C, 37(8), 2001, pp. 2059-2065
41. Neumann, FJ; Hochholzer, W; Pogatsa-Murray, G; Schomig, A; Gawaz, M
    Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    
    F.J. Neumann et al., "Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting", J AM COL C, 37(5), 2001, pp. 1323-1328
42. Lev, EI; Osende, JI; Richard, MF; Robbins, JA; Delfin, JA; Rodriguez, O; Sharma, SK; Jayasundera, T; Badimon, JJ; Marmur, JD
    Administration of abciximab to patients receiving tirofiban or eptifibatide: Effect on platelet function
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    
    E.I. Lev et al., "Administration of abciximab to patients receiving tirofiban or eptifibatide: Effect on platelet function", J AM COL C, 37(3), 2001, pp. 847-855
43. Salvati, F; Liani, M
    Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
    
    F. Salvati e M. Liani, "Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis", INT J ARTIF, 24(3), 2001, pp. 131-135
44. Rossi, F; Rossi, E; Pareti, FI; Colli, S; Tremoli, E; Gallo, L
    In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion
    HAEMATOLOGICA
    
    F. Rossi et al., "In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion", HAEMATOLOG, 86(2), 2001, pp. 192-198
45. Keh, D; Kurer, I; Dudenhausen, JW; Woltmann, W; Falke, KJ; Gerlach, H
    Response of neonatal platelets to nitric oxide in vitro
    INTENSIVE CARE MEDICINE
    
    D. Keh et al., "Response of neonatal platelets to nitric oxide in vitro", INTEN CAR M, 27(1), 2001, pp. 283-286
46. Goldmann, BU; Hamm, CW
    Risk stratification in acute coronary syndrome
    HERZ
    
    B.U. Goldmann e C.W. Hamm, "Risk stratification in acute coronary syndrome", HERZ, 26, 2001, pp. 24-29
47. Schror, K
    Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa antagonists
    HERZ
    
    K. Schror, "Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa antagonists", HERZ, 26, 2001, pp. 30-35
48. Rendu, F; Brohard-Bohn, B; Pain, S; Bachelot-Loza, C; Auger, J
    Thiosulfinates inhibit platelet aggregation and microparticle shedding at a calpain-dependent step
    THROMBOSIS AND HAEMOSTASIS
    
    F. Rendu et al., "Thiosulfinates inhibit platelet aggregation and microparticle shedding at a calpain-dependent step", THROMB HAEM, 86(5), 2001, pp. 1284-1291
49. Topaz, O; Minisi, AJ; Bernardo, NL; McPherson, RA; Martin, E; Carr, SL; Carr, ME
    Alterations of platelet aggregation kinetics with ultraviolet laser emission: The "stunned platelet" phenomenon
    THROMBOSIS AND HAEMOSTASIS
    
    O. Topaz et al., "Alterations of platelet aggregation kinetics with ultraviolet laser emission: The "stunned platelet" phenomenon", THROMB HAEM, 86(4), 2001, pp. 1087-1093
50. Derrick, JM; Shattil, SJ; Poncz, M; Gruppo, RA; Gartner, TK
    Distinct domains of alpha IIb beta 3 support different aspects of outside-in signal transduction and platelet activation induced by LSARLAF, an alphaIIb beta 3 interacting peptide
    THROMBOSIS AND HAEMOSTASIS
    
    J.M. Derrick et al., "Distinct domains of alpha IIb beta 3 support different aspects of outside-in signal transduction and platelet activation induced by LSARLAF, an alphaIIb beta 3 interacting peptide", THROMB HAEM, 86(3), 2001, pp. 894-901
51. Marques, JA; George, JK; Smith, IJ; Bhakta, V; Sheffield, WP
    A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro
    THROMBOSIS AND HAEMOSTASIS
    
    J.A. Marques et al., "A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro", THROMB HAEM, 86(3), 2001, pp. 902-908
52. Fox, JEB
    Cytoskeletal proteins and platelet signaling
    THROMBOSIS AND HAEMOSTASIS
    
    J.E.B. Fox, "Cytoskeletal proteins and platelet signaling", THROMB HAEM, 86(1), 2001, pp. 198-213
53. Shattil, SJ; Leavitt, AD
    All in the family: Primary megakaryocytes for studies of platelet alpha IIb beta(3) signaling
    THROMBOSIS AND HAEMOSTASIS
    
    S.J. Shattil e A.D. Leavitt, "All in the family: Primary megakaryocytes for studies of platelet alpha IIb beta(3) signaling", THROMB HAEM, 86(1), 2001, pp. 259-265
54. Woodside, DG; Liu, S; Ginsberg, MH
    Integrin activation
    THROMBOSIS AND HAEMOSTASIS
    
    D.G. Woodside et al., "Integrin activation", THROMB HAEM, 86(1), 2001, pp. 316-323
55. Coller, BS
    Anti-GPIIb/IIIa drugs: Current strategies and future directions
    THROMBOSIS AND HAEMOSTASIS
    
    B.S. Coller, "Anti-GPIIb/IIIa drugs: Current strategies and future directions", THROMB HAEM, 86(1), 2001, pp. 427-443
56. Sassoli, PM; Emmell, EL; Tam, SH; Trikha, M; Zhou, Z; Jordan, RE; Nakada, MT
    7E3 F(ab ')(2), an effective antagonist of rat alpha IIb beta 3 and alpha v beta 3, blocks in vivo thrombus formation and in vitro angiogenesis
    THROMBOSIS AND HAEMOSTASIS
    
    P.M. Sassoli et al., "7E3 F(ab ')(2), an effective antagonist of rat alpha IIb beta 3 and alpha v beta 3, blocks in vivo thrombus formation and in vitro angiogenesis", THROMB HAEM, 85(5), 2001, pp. 896-902
57. Bennett, JS; Mousa, S
    Platelet function inhibitors in the year 2000
    THROMBOSIS AND HAEMOSTASIS
    
    J.S. Bennett e S. Mousa, "Platelet function inhibitors in the year 2000", THROMB HAEM, 85(3), 2001, pp. 395-400
58. Bauer, M; Maschberger, P; Quek, L; Briddon, SJ; Dash, D; Weiss, M; Watson, SP; Siess, W
    Genetic and pharmacological analyses of involvement of Src-family, Syk andBtk tyrosine kinases in platelet shape change - Src-kinases mediate integrin alpha(IIb)beta(3) inside-out signaling during shape change
    THROMBOSIS AND HAEMOSTASIS
    
    M. Bauer et al., "Genetic and pharmacological analyses of involvement of Src-family, Syk andBtk tyrosine kinases in platelet shape change - Src-kinases mediate integrin alpha(IIb)beta(3) inside-out signaling during shape change", THROMB HAEM, 85(2), 2001, pp. 331-340
59. Israels, SJ; McMillan-Ward, EM; Easton, J; Robertson, C; McNicol, A
    CD63 associates with the alpha(IIb)beta(3) integrin-CD9 complex on the surface of activated platelets
    THROMBOSIS AND HAEMOSTASIS
    
    S.J. Israels et al., "CD63 associates with the alpha(IIb)beta(3) integrin-CD9 complex on the surface of activated platelets", THROMB HAEM, 85(1), 2001, pp. 134-141
60. Klinkhardt, U; Graff, J; Westrup, D; Kirchmaier, CM; Esslinger, HU; Breddin, HK; Harder, S
    Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    U. Klinkhardt et al., "Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects", BR J CL PH, 52(3), 2001, pp. 297-305
61. Graff, J; Andries, D; Elsner, M; Westrup, D; Bassus, S; Franz, N; Klinkhardt, U; Harder, S
    Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    J. Graff et al., "Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab", BR J CL PH, 51(6), 2001, pp. 577-582
62. Dopheide, SM; Yap, CL; Jackson, SP
    Dynamic aspects of platelet adhesion under flow
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    
    S.M. Dopheide et al., "Dynamic aspects of platelet adhesion under flow", CLIN EXP PH, 28(5-6), 2001, pp. 355-363
63. Boudreaux, MK; Lipscomb, DL
    Clinical, biochemical, and molecular aspects of Glanzmann's thrombastheniain humans and dogs
    VETERINARY PATHOLOGY
    
    M.K. Boudreaux e D.L. Lipscomb, "Clinical, biochemical, and molecular aspects of Glanzmann's thrombastheniain humans and dogs", VET PATH, 38(3), 2001, pp. 249-260
64. Galeote, G; Pastor, AA; Carcamo, C; Sobrino, N; Calvo, L; Munoz, SG; Hussein, M; Fernandez-Chacon, JL; Sobrino, JA
    Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty
    REVISTA ESPANOLA DE CARDIOLOGIA
    
    G. Galeote et al., "Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty", REV ESP CAR, 54(11), 2001, pp. 1256-1263
65. Cokkinos, DV
    The treatment of coronary heart disease: An update - Part 4: Acute ischaemic coronary syndromes
    CURRENT MEDICAL RESEARCH AND OPINION
    
    D.V. Cokkinos, "The treatment of coronary heart disease: An update - Part 4: Acute ischaemic coronary syndromes", CURR MED R, 17(1), 2001, pp. 38-40
66. Mathis, AS; Meswani, P; Spinler, SA
    Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines
    PHARMACOTHERAPY
    
    A.S. Mathis et al., "Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines", PHARMACOTHE, 21(8), 2001, pp. 954-987
67. Spinler, SA; Inverso, SM
    Update on strategies to improve thrombolysis for acute myocardial infarction
    PHARMACOTHERAPY
    
    S.A. Spinler e S.M. Inverso, "Update on strategies to improve thrombolysis for acute myocardial infarction", PHARMACOTHE, 21(6), 2001, pp. 691-716
68. McKay, RG; Boden, WE
    Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials
    CURRENT OPINION IN CARDIOLOGY
    
    R.G. McKay e W.E. Boden, "Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials", CURR OPIN C, 16(6), 2001, pp. 364-369
69. Chan, AW; Moliterno, DJ
    Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO v, and TARGET
    CURRENT OPINION IN CARDIOLOGY
    
    A.W. Chan e D.J. Moliterno, "Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO v, and TARGET", CURR OPIN C, 16(6), 2001, pp. 375-383
70. Chang, CP; Chang, JC; Chang, HH; Tsai, WJ; Lo, SCJ
    Positional importance of Pro(53) adjacent to the Arg(49)-Gly(50)-Asp(51) sequence of rhodostomin in binding to integrin alpha IIb beta 3
    BIOCHEMICAL JOURNAL
    
    C.P. Chang et al., "Positional importance of Pro(53) adjacent to the Arg(49)-Gly(50)-Asp(51) sequence of rhodostomin in binding to integrin alpha IIb beta 3", BIOCHEM J, 357, 2001, pp. 57-64
71. Gimeno, MJ; Gonzalez, J; Rodriguez, M; Corrales, C; Bellon, JM; Bujan, J
    Potential role of a new anti-beta 3 integrin antibody in the development of intimal hyperplasia after vascular surgery: an in vitro smooth muscle cell model
    HISTOLOGY AND HISTOPATHOLOGY
    
    M.J. Gimeno et al., "Potential role of a new anti-beta 3 integrin antibody in the development of intimal hyperplasia after vascular surgery: an in vitro smooth muscle cell model", HIST HISTOP, 16(3), 2001, pp. 821-826
72. Nicholson, NS; Abood, NA; Panzer-Knodle, SG; Frederick, LG; Page, JD; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB; Anders, RJ
    Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist
    MEDICINAL RESEARCH REVIEWS
    
    N.S. Nicholson et al., "Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist", MED RES REV, 21(3), 2001, pp. 211-226
73. Christov, A; Kostuk, WJ; Jablonsky, G; Lucas, A
    Fluorescence spectroscopic analysis of circulating platelet activation during coronary angioplasty
    LASERS IN SURGERY AND MEDICINE
    
    A. Christov et al., "Fluorescence spectroscopic analysis of circulating platelet activation during coronary angioplasty", LASER SURG, 28(5), 2001, pp. 414-426
74. Tcheng, JE; Strony, J; Lorenz, TJ; O'Shea, JC
    ESPRIT in context: pharmacology matters!
    EUROPEAN HEART JOURNAL
    
    J.E. Tcheng et al., "ESPRIT in context: pharmacology matters!", EUR HEART J, 22(21), 2001, pp. 1965-1967
75. Loubeyre, C; Lefevre, T; Louvard, Y; Dumas, P; Piechaud, JF; Lanore, JJ; Angellier, JF; Le Tarnec, JY; Karrillon, G; Margenet, A; Pouges, C; Morice, MC
    Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent
    EUROPEAN HEART JOURNAL
    
    C. Loubeyre et al., "Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent", EUR HEART J, 22(13), 2001, pp. 1128-1135
76. Hallahan, DE; Geng, L; Cmelak, AJ; Chakravarthy, AB; Martin, W; Scarfone, C; Gonzalez, A
    Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature
    JOURNAL OF CONTROLLED RELEASE
    
    D.E. Hallahan et al., "Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature", J CONTR REL, 74(1-3), 2001, pp. 183-191
77. Zwart-van Rijkom, JEF; Klungel, OH; Leufkens, HGM; Broekmans, AW; Schrijver-van Velthoven, S; Umans, VA
    Costs and effects of combining stenting and abciximab (ReoPro (R)) in daily practice
    INTERNATIONAL JOURNAL OF CARDIOLOGY
    
    J.E.F. Zwart-van Rijkom et al., "Costs and effects of combining stenting and abciximab (ReoPro (R)) in daily practice", INT J CARD, 77(2-3), 2001, pp. 299-303
78. Hantgan, RR; Stahle, M; Del Gaizo, V; Adams, M; Lasher, T; Jerome, WG; McKenzie, M; Lyles, DS
    alpha IIb's cytoplasmic domain is not required for ligand-induced clustering of integrin alpha IIb beta 3
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
    
    R.R. Hantgan et al., "alpha IIb's cytoplasmic domain is not required for ligand-induced clustering of integrin alpha IIb beta 3", BBA-MOL CEL, 1540(1), 2001, pp. 82-95
79. Suvire, FD; Rodriguez, AM; Mak, ML; Papp, JG; Enriz, RD
    Binding mechanism of RGD and its mimetics to receptor GPIIb/IIIa. A theoretical study
    JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
    
    F.D. Suvire et al., "Binding mechanism of RGD and its mimetics to receptor GPIIb/IIIa. A theoretical study", J MOL ST-TH, 540, 2001, pp. 257-270
80. Latham, C; Zhang, AJ; Nalbanti, A; Maner, S; Zickert, P; Blegen, H; Zetterberg, A
    Frequent co-amplification of two different regions on 17q in aneuploid breast carcinomas
    CANCER GENETICS AND CYTOGENETICS
    
    C. Latham et al., "Frequent co-amplification of two different regions on 17q in aneuploid breast carcinomas", CANC GENET, 127(1), 2001, pp. 16-23
81. Fry, ETA
    Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: A combined role in coronary interventions?
    CLINICAL CARDIOLOGY
    
    E.T.A. Fry, "Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: A combined role in coronary interventions?", CLIN CARD, 24(3), 2001, pp. I8-I11
82. Kang, WS; Chung, KH; Chung, JH; Lee, JY; Park, JB; Zhang, YH; Yoo, HS; Yun, YP
    Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    
    W.S. Kang et al., "Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase", J CARDIO PH, 38(6), 2001, pp. 875-884
83. Amoroso, G; van Boven, AJ; van Veldhuisen, DJ; Tio, RA; Balje-Volkers, CP; Petronio, AS; van Oeveren, W
    Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients withcoronary artery disease
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    
    G. Amoroso et al., "Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients withcoronary artery disease", J CARDIO PH, 38(4), 2001, pp. 633-641
84. Truong, KM; Amankwa, K; Kucukarslan, S
    Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review
    CLINICAL THERAPEUTICS
    
    K.M. Truong et al., "Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review", CLIN THER, 23(8), 2001, pp. 1145-1165
85. Qureshi, AI; Ali, Z; Suri, MFK; Kim, SH; Fessler, RD; Ringer, AJ; Guterman, LR; Hopkins, LN
    Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement
    NEUROSURGERY
    
    A.I. Qureshi et al., "Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement", NEUROSURGER, 48(5), 2001, pp. 998-1004
86. Akkerhuis, KM; Deckers, JW; Lincoff, AM; Tcheng, JE; Boersma, E; Anderson, K; Balog, C; Califf, RM; Topol, EJ; Simoons, ML
    Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    
    K.M. Akkerhuis et al., "Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention", J AM MED A, 286(1), 2001, pp. 78-82
87. Pu, Q; Wiel, E; Corseaux, D; Bordet, R; Azrin, MA; Ezekowitz, MD; Lund, N; Jude, B; Vallet, B
    Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endotheliumin Escherichia coli endotoxin-induced shock
    CRITICAL CARE MEDICINE
    
    Q. Pu et al., "Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endotheliumin Escherichia coli endotoxin-induced shock", CRIT CARE M, 29(6), 2001, pp. 1181-1188
88. Parker, RI
    IIb/IIIa or not IIb/IIIa, that is adhesion
    CRITICAL CARE MEDICINE
    
    R.I. Parker, "IIb/IIIa or not IIb/IIIa, that is adhesion", CRIT CARE M, 29(6), 2001, pp. 1286-1287
89. Bennett, JS
    Novel platelet inhibitors
    ANNUAL REVIEW OF MEDICINE
    
    J.S. Bennett, "Novel platelet inhibitors", ANN R MED, 52, 2001, pp. 161-184
90. Park, JW; Smolen, J
    Monoclonal antibody therapy
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    
    J.W. Park e J. Smolen, "Monoclonal antibody therapy", ADV PROTEIN, 56, 2001, pp. 369-421
91. Wang, XF; Liu, FQ; Morris, SA; Carroll, RC
    Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization
    THROMBOSIS RESEARCH
    
    X.F. Wang et al., "Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization", THROMB RES, 104(4), 2001, pp. 239-247
92. Sakariassen, KS; Hanson, SR; Cadroy, Y
    Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy
    THROMBOSIS RESEARCH
    
    K.S. Sakariassen et al., "Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy", THROMB RES, 104(3), 2001, pp. 149-174
93. Damiano, BP; Mitchell, JA; Giardino, E; Corcoran, T; Haertlein, BJ; de Garavilla, L; Kauffman, JA; Hoekstra, WJ; Maryanoff, BE; Andrade-Gordon, P
    Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist
    THROMBOSIS RESEARCH
    
    B.P. Damiano et al., "Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist", THROMB RES, 104(2), 2001, pp. 113-126
94. Cook, BC
    Reactivity of human platelets with immobilized fibrinogen is dictated by the chemical character of the surface
    THROMBOSIS RESEARCH
    
    B.C. Cook, "Reactivity of human platelets with immobilized fibrinogen is dictated by the chemical character of the surface", THROMB RES, 104(1), 2001, pp. 39-48
95. Mousa, SA; Forsythe, MS
    Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography
    THROMBOSIS RESEARCH
    
    S.A. Mousa e M.S. Forsythe, "Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography", THROMB RES, 104(1), 2001, pp. 49-56
96. Erhardt, JA; Ohlstein, EH; Toomey, JR; Gabriel, MA; Willette, RN; Yue, TL; Barone, FC; Parsons, AA
    Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban
    THROMBOSIS RESEARCH
    
    J.A. Erhardt et al., "Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban", THROMB RES, 103(2), 2001, pp. 143-148
97. Peter, K; Schwarz, M; Nordt, T; Bode, C
    Intrinsic activating properties of GP IIb/IIIa blockers
    THROMBOSIS RESEARCH
    
    K. Peter et al., "Intrinsic activating properties of GP IIb/IIIa blockers", THROMB RES, 103, 2001, pp. S21-S27
98. Rossi, ML; Merlini, PA; Ardissino, D
    Percutaneous coronary revascularisation in women
    THROMBOSIS RESEARCH
    
    M.L. Rossi et al., "Percutaneous coronary revascularisation in women", THROMB RES, 103, 2001, pp. S105-S111
99. Verheugt, FWA
    GP IIB/IIIA blockers with and without thrombolytic agent in prehospital treatment of acute myocardial infarction
    THROMBOSIS RESEARCH
    
    F.W.A. Verheugt, "GP IIB/IIIA blockers with and without thrombolytic agent in prehospital treatment of acute myocardial infarction", THROMB RES, 103, 2001, pp. S113-S116
100. Darius, H
     Oral glycoprotein Ilb/IIa antagonists for unstable angina - Is there stilla chance for the oral substances?
     THROMBOSIS RESEARCH
     
     H. Darius, "Oral glycoprotein Ilb/IIa antagonists for unstable angina - Is there stilla chance for the oral substances?", THROMB RES, 103, 2001, pp. S117-S124